China (Mainland)
- Product Details
Keywords
- AZD9291
- Osimertinib mesylate
- 1421373-66-1
Quick Details
- ProName: Osimertinib mesylate
- CasNo: 1421373-66-1
- Molecular Formula: C29H37N7O5S
- Appearance: white powder
- Application: API
- DeliveryTime: within 3-7 day
- PackAge: As required
- Port: shanghai or other
- ProductionCapacity: 100 Kilogram/Month
- Purity: 99（%）
- Storage: Room temperature
- Transportation: by sea or by air
- LimitNum: 1 Gram
Superiority
Changzhou Xuanming Chemical Co., Ltd. is dedicated to the technology development, manufacturing, import and export chemicals, which are specialized in pharmaceutical intermediates, pesticide intermediate, industry of fine chemicals and custom synthesis. Now, we enjoy good reputation among customers and take favorable market share in domestic and at abroad.
Changzhou Xuanming Chemical CO., LTD is located in Northern Jiangshu Industry Park, we have modern manufacture bases and some laboratories, which can supply the key intermediate for your projects, and short your synthesis scheme and supply you a reference compound for bioassay or a high purity analytical standard. We have been abided by “treat technology as first, quality as basis, customers as God, and be honest and sincere”. It is our final aim to provide environmental and high technological products and meet customers’ requirements according to keep effors on developing new chemical fields.
Changzhou Xuanming Chemical CO., LTD promises to help you with heart and soul.
Details
| Osimertinib mesylate Basic information |
| Product Name: | Osimertinib mesylate |
| Synonyms: | Mesylate-AZD9291;Osimertinib d6;N-(2-(N-(2-(dimethylamino)ethyl)-N-methylamino)-4-methoxy-5-((4-(1-methyl-1H-indole-3-yl)pyrimidine-2-yl)amino)phenyl)acrylamide methanesulfonate;Osimertinib methanesulfonate;Osimertinib (AZD9291) mesylate;Mereletinib mesylate, 98%, a potent and selective mutated forms EGFR inhibitor;AZD-9291 mesylate (Osimertinib mesylate;AZD-9291 mesylate (Osimertinib,Mereletinib) |
| CAS: | 1421373-66-1 |
| MF: | C29H37N7O5S |
| MW: | 595.71298 |
| EINECS: | |
| Product Categories: | -;AZD09 |
| Mol File: | 1421373-66-1.mol |
|
|
|
| Osimertinib mesylate Chemical Properties |
| Safety Information |
| HS Code | 29339900 |
| Osimertinib mesylate Usage And Synthesis |
| Definition | ChEBI: A methanesulfonate (mesylate) salt prepared from equimolar amounts of osimertinib and methanesulfonic acid. Used for treatment of EGFR T790M mutation positive non-small cell lung cancer. |
| Indications | The collection of ibrutinib (Imbruvica(R), Pharmacyclics Inc.), afatinib, and osimertinib represents the small, yet expanding, group of covalent SMKIs. Ibrutinib is a non-receptor Bruton’s tyrosine kinase inhibitor approved for the treatment of relapsed chronic lymphocytic leukemia. Afatinib, approved for NSCLC in 2013 and squamous NSCLC in 2016, is a second-generation irreversible EGFR inhibitor that targets wild-type EGFR, the mutant T790M EGFR, and HER2. Osimertinib (AZD9291), which was approved by FDA in November 2015, is a third-generation irreversible EGFR inhibitor that selectively targets the mutant T790M EGFR. Rociletinib, which shares a high degree of structural similarity with that of osimertinib, is a promising covalent EGFR inhibitor developed by Clovis Oncology aimed for the treatment of patients with EGFR T790M-mutated NSCLC, until the company terminated its development in May 2016 following a negative vote fromthe FDA’sOncologic Drugs Advisory Committee. |
|
Osimertinib mesylate Preparation Products And Raw materials |
